


Catalog Number: CM04472

产品信息

Catalog Number:
CM04472CAS号:
1672665-49-4分子式:
C₁₇H₁₂F₃NO₄S主要靶点:
HIF/HIF Prolyl-Hydroxylase|HIF主要通路:
表观遗传|血管生成|代谢分子量:
383.34溶解度:
DMSO:50 mg/mL (130.43 mM)

靶点活性

HIF-2 α :<50 nM (Kd)

体外活性

PT-2385 is a selective antagonist of HIF-2 and inactive for HIF-1 α [1].

体内活性

PT-2385 inhibits expression of HIF-2 α regulated genes in a dose dependent manner in vivo. Tumor is regressed with PT-2385 (3 and 10 mg/kg, p.o., b.i.d. dose) in 786-O xenograft. PT-2385 (1,3 and 10 mg/kg) also inhibits tumor-derived VEGFA protein levels. PT-2385 (10 mg/kg) treatment reduces proliferation (Ki67) and angiogenesis (CD-31) [1]. PT-2385 (30 or 100 mg/kg; oral gavage; twice daily) result in a rapid, dose-dependent tumor regression [2].

动物实验

Animal Model: SCID/beige mice with the 786-O and A498 RCC cell lines. Dosage: 30 or 100 mg/kg.
Administration: Oral gavage; twice daily [2]

描述

PT-2385 is a selective HIF-2 α inhibitor (Kd<50 nM).

储存

Powder: -20°C for 3 years | In solvent: -80°C for 2 years